GlaxoSmithKline voluntarily issued a recall Wednesday for over 430,000 bottles of Excedrin due to a manufacturing defect that may have left holes in the bottom of the drug that relieves pain.
Company officials said some of the bottles containing the over-the-counter drug could have a hole in the bottom.
Officials say if there is a hole, children could access and swallow the contents, posing a poisoning risk. These products contain the substances aspirin and acetaminophen, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act (PPPA).
The full recall includes many of the company’s over-the-counter aspirin- and acetaminophen-based products sold nationwide between March 2018 and September 2020.
No injuries or incidents have been reported, but the products – sold under the brand names Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets, and Excedrin Tension Headache Caplets – have been deemed to violate the Poison Prevention Packaging Act.
The act mandates childproof packaging for a lengthy list of potentially hazardous household products, including over-the-counter and prescription drugs.